www.aoa.gov/AoARoot/Grants/Reporting_Requirements/docs/FinalReportHandbook.doc. ACL estimates the burden of this collection of information as follows: *Frequency:* Semi-annually with the Final report taking the place of the semi-annual report at the end of the final year of the grant. *Respondents:* States, public agencies, private nonprofit agencies, institutions of higher education, and organizations including tribal organizations. *Estimated Number of Responses:* 600. *Total Estimated Burden Hours:* 12,000.

Dated: August 3, 2012.

Kathy Greenlee,

Administrator and Assistant Secretary for Aging.

[FR Doc. 2012–19453 Filed 8–7–12; 8:45 am]

BILLING CODE 4154–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2011–N–0608]

Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; MedWatch: The Food and Drug Administration Medical Products Reporting Program

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that a collection of information entitled ''MedWatch: The Food and Drug Administration Medical Products Reporting Program'' has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.

FOR FURTHER INFORMATION CONTACT: Jonna Capezzuto, Office of Information Management, Food and Drug Administration, 1350 Piccard Dr., PI50–400B, Rockville, MD 20850, 301–796–3794, *Jonnalynn.Capezzuto@fda.hhs.gov.*

SUPPLEMENTARY INFORMATION: On June 28, 2012, the Agency submitted a proposed collection of information entitled ''MedWatch: The Food and Drug Administration Medical Products Reporting Program'' to OMB for review and clearance under 44 U.S.C. 3507. An Agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. OMB has now approved the information collection and has assigned OMB control number 0910–0291. The approval expires on June 30, 2015. A copy of the supporting statement for this information collection is available on the Internet at *http://www.reginfo.gov/public/do/PRAMain.*

Dated: August 3, 2012.

David Dorsey,

Acting Associate Commissioner for Policy and Planning.

[FR Doc. 2012–19377 Filed 8–7–12; 8:45 am]

BILLING CODE 4160–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2012–N–0793]

Request for Nominations of Specific Drug/Biologic Product(s) That Could Be Brought Before the Food and Drug Administration's Pediatric Subcommittee of the Oncologic Drugs Advisory Committee

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; request for product nominations.

SUMMARY: The Food and Drug Administration's (FDA) Office of Hematology and Oncology Products invites the public to suggest one or more specific drug or biologic products that could be brought before the December 4, 2012, Pediatric Subcommittee of the Oncologic Drugs Advisory Committee (ODAC). The number of drugs studied for use in pediatric patients is growing, and we see a reduction in off-label use. However, we would like to improve current and future pediatric product development by focusing on products whose development would benefit the most from the attention of an advisory committee. The company developing a product that is brought before the committee will be given the unique opportunity to present proposed pediatric studies in the United States, share their plans for global pediatric development, and hear discussions by the Pediatric Subcommittee on possible directions for their current or future pediatric oncology product development.

DATES: Nominations must be received by September 4, 2012, to receive consideration for inclusion. Nominations received after this date will receive consideration for future meetings of the Pediatric Subcommittee of the ODAC.

ADDRESSES: Email nominations to *Christine.Lincoln@fda.hhs.gov,* and please include the subject line ''Suggested Product for 2012 Pediatric Oncology Subcommittee of ODAC.''

FOR FURTHER INFORMATION CONTACT: Christine Lincoln, RN, MS, MBA, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 22, Rm. 2206, Silver Spring, MD 20993, 301–796–4117, *Christine.Lincoln@fda.hhs.gov.*

SUPPLEMENTARY INFORMATION: The Food and Drug Administration (FDA) Advisory Committees are an important, transparent interface that allows the Agency to include the public in its decision-making processes. Significant public health and safety issues are brought before these committees for deliberation, and the meetings bring together both experts with state-of-the-art knowledge and members of the public with relevant personal experiences. This broad participation gives FDA a unique perspective as it seeks to assure the safety, efficacy, and security of FDA-regulated products.

Additional information about the prior November 2, 2011, Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee may be found on FDA's Web site at: *http://www.fda.gov/AdvisoryCommittees/Calendar/ucm274396.htm.*

Dated: August 2, 2012.

Leslie Kux,

Assistant Commissioner for Policy.

[FR Doc. 2012–19330 Filed 8–7–12; 8:45 am]

BILLING CODE 4160–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Services Administration

Statement of Organization, Functions and Delegations of Authority

This notice amends Part R of the Statement of Organization, Functions and Delegations of Authority of the Department of Health and Human Services (HHS), Health Resources and Services Administration (HRSA) (60 FR 56605, as amended November 6, 1995; as last amended at 77 FR 46098–46099 dated August 2, 2012).

This notice reflects organizational changes in the Health Resources and Services Administration (HRSA). Specifically, this notice updates the functional statement for both the Office of Operations (RB) and the Office of Management (RB4) to include the human resources function for HRSA;